title: Gastrointestinal irritancy, antiinflammatory activity, and prostanoid inhibition in the rat. Differentiation of effects between nabumetone and etodolac.
abstract: Many nonsteroidal antiinflammatory drugs have the ability to cause gastrointestinal damage in both animals and man. The aim of the present study was to compare nabumetone, a nonacidic drug, with etodolac on rat gastric mucosal damage and prostanoid synthesis, while concurrently measuring prostanoid production during edema formation in a carrageenan model of paw inflammation. The results showed that both drugs inhibited paw exudate prostaglandin E2 and edema significantly, but they did not inhibit gastric prostanoid production 4 hr after dosing. Gastric damage, however, was observed with etodolac. Additional time-course studies showed that over a 4-hr period, etodolac, unlike nabumetone, markedly inhibited gastric mucosal prostaglandin E2 production, which was associated with gastric erosion formation. Further studies demonstrated that nabumetone did not induce gastrointestinal damage or blood loss when administered to rats in a high antiinflammatory oral dose. In contrast, etodolac produced marked gastrointestinal damage and bleeding, which was evident for up to 48 hr after the dose. It is suggested that nabumetone's favorable gastrointestinal irritancy profile may relate, in part, to its nonacidic nature and to its differential effects on prostanoid production.
authors.affiliation: SmithKline Beecham Pharmaceuticals, Research and Development Technologies, Harlow, Essex, UK.
authors.forename: R
authors.initials: R
authors.lastname: Melarange
authors.forename: C
authors.initials: C
authors.lastname: Gentry
authors.forename: M
authors.initials: M
authors.lastname: Durie
authors.forename: C
authors.initials: C
authors.lastname: O'Connell
authors.forename: P R
authors.initials: PR
authors.lastname: Blower
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D002074:Butanones / Q000494:pharmacology*; D002432:Cecum / Q000737:chemistry; D003864:Depression, Chemical; D015232:Dinoprostone / Q000096:biosynthesis*; D004487:Edema / Q000139:chemically induced / Q000378:metabolism; D017308:Etodolac / Q000494:pharmacology*; D005753:Gastric Mucosa / Q000187:drug effects*; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006242:Haptoglobins / Q000032:analysis; D006454:Hemoglobins / Q000032:analysis; D007413:Intestinal Mucosa / Q000187:drug effects*; D008297:Male; D000077430:Nabumetone; D051381:Rats; D017208:Rats, Wistar
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D002074:Butanones; D006242:Haptoglobins; D006454:Hemoglobins; D017308:Etodolac; D015121:6-Ketoprostaglandin F1 alpha; D015232:Dinoprostone; D000077430:Nabumetone